Increase activity Exercise offers many additional health benefits, including a more positive mood, improved metabolic health, and a boost to cardiovascular health, among many others
doi: 10.1007/s10620-013-2715-9
It places stronger emphasis on Phase III outcomes, making adoption (by government or the private sector) and revenue the true measures of success, rather than just completing R&D
Key Takeaways Triple agonist mechanism: Retatrutide is the first medication to activate GIP, GLP-1, and glucagon receptors simultaneously GLP-1 component reduces appetite and slows gastric emptying, the core appetite suppression pathway GIP component improves insulin sensitivity and promotes favorable fat distribution Glucagon component increases energy expenditure through thermogenesis and promotes fat breakdown Weight loss: Phase 2 trials showed up to 24.2% weight loss at 48 weeks, compared to tirzepatide (~22%) and semaglutide (~15%) Investigational status: Not FDA-approved
It is often the final step in feeling fully aligned with your effort and progress
But, a lot has changed since last summer and the numbers are something else